US EditionFrom No Hope to a Potential Cure for a Deadly Blood Cancer
- Ninety-Seven individuals suffering from advanced multiple myeloma participated in a final-attempt immunotherapy study conducted in recent years.
- Doctors considered multiple myeloma incurable and fatal within about a year, with painful bone damage and no effective treatments remaining.
- The immunotherapy, a CAR-T treatment developed by Legend Biotech, used engineered white blood cells to attack the cancer and revolutionized outcomes in blood cancers like leukemia.
- Approximately one-third of patients experienced complete remission of their cancer that lasted for at least five years, leading experts like Dr. Norman Sharpless to acknowledge that this marks a significant shift toward considering multiple myeloma potentially curable.
- This result raises hope for multiple myeloma patients despite the treatment's high cost exceeding US$555,000, and experts see potential cure if used earlier in therapy.
Insights by Ground AI
Does this summary seem wrong?
5 Articles
5 Articles
All
Left
Center
2
Right
2
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsMyeloma Trial Results Spark Talk of 'Potential Cure'
One-third of patients alive and progression-free 5 or more years after a single infusion
·New York, United States
Read Full Article
Coverage Details
Total News Sources5
Leaning Left0Leaning Right2Center2Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
